Market closedNon-fractional
Veracyte/VCYT
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Veracyte
Ticker
VCYT
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
South San Francisco, United States
Employees
815
Website
www.veracyte.com
Veracyte Metrics
BasicAdvanced
$1.6B
Market cap
-
P/E ratio
-$0.93
EPS
1.70
Beta
-
Dividend rate
Price and volume
Market cap
$1.6B
Beta
1.7
Financial strength
Current ratio
5.003
Quick ratio
4.407
Long term debt to equity
0.72
Total debt to equity
1.255
Interest coverage (TTM)
-797.25%
Management effectiveness
Return on assets (TTM)
-0.64%
Return on equity (TTM)
-6.20%
Valuation
Price to revenue (TTM)
4.15
Price to book
1.46
Price to tangible book (TTM)
6.58
Price to free cash flow (TTM)
59.19
Growth
Revenue change (TTM)
20.66%
Earnings per share change (TTM)
121.19%
3-year revenue growth
45.04%
3-year earnings per share growth
-6.80%
What the Analysts think about Veracyte
Analyst Ratings
Majority rating from 9 analysts.
Veracyte Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$97M
-1.33%
Net income
-$1.8M
-93.62%
Profit margin
-1.85%
-93.56%
Veracyte Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.12
-$0.41
-$0.39
-$0.02
-
Expected
-$0.15
-$0.15
-$0.09
-$0.16
-$0.03
Surprise
-21.44%
179.62%
317.86%
-87.41%
-
Veracyte News
AllArticlesVideos
Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors
Business Wire·1 month ago
Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
Business Wire·1 month ago
Veracyte to Participate in Upcoming Investor Conferences
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Veracyte stock?
Veracyte (VCYT) has a market cap of $1.6B as of July 05, 2024.
What is the P/E ratio for Veracyte stock?
The price to earnings (P/E) ratio for Veracyte (VCYT) stock is 0 as of July 05, 2024.
Does Veracyte stock pay dividends?
No, Veracyte (VCYT) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next Veracyte dividend payment date?
Veracyte (VCYT) stock does not pay dividends to its shareholders.
What is the beta indicator for Veracyte?
Veracyte (VCYT) has a beta rating of 1.7. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Veracyte stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.